Login Register
E-ISSN : 2148-9696
Crescent Journal of
Medical and Biological Sciences
Apr 2017, Vol 4, Issue 2
Advanced Search
Title
Authors
Keyword
Poll
How do you find the scientific quality of the published articles on our web site?
Original Article
Comparison of Azithromycin and Pyrimethamine/Sulfadiazine Treatment in Ocular Toxoplasmosis in North West of Iran
Leila Alizadeh Ghavidel, Amir Eftekhari Milani, Masood Bagheri
Department of Ophthalmology, Nikookakari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran

CJMB 2017; 4: 080-084

Viewed : 203 times
Downloaded : 228 times.

Keywords : Azithromycin, Toxoplasmosis, Uveitis, Chorioretinitis
Full Text(PDF) | Related Articles
Abstract
Objective: Ocular toxoplasmosis (OT), characterized by necrotizing retinochoroiditis, scar formation and decreased vision, is recognized as the most prevalent cause of posterior uveitis in Iran. Although pyrimethamine/sulfadiazine combination remains the standard treatment particularly for patients with sight-threatening lesions, intolerance, inaccessibility and adverse drug reactions to this regimen have imposed us to seek for alternative treatments.

Materials and Methods: In this prospective randomized control clinical trial study, 72 patients with active, non-vision threatening toxoplasmic chorioretinitis were randomly divided into 2 treatment regimen: 36 patients treated with standard protocol with pyrimethamine/sulfadiazine, and 36 patients received azithromycin for 6 weeks. All patients were followed up for 24 months. The clinical outcomes measured before and after intervention were, time to disease inactivity (lesion borders sharpening and scarring), changes in the size of retinochoroidal lesion, rate of recurrence, adverse drug reactions and visual acuity (VA).

Results: No significant difference was noted between the 2 groups regarding age, gender, and VA before treatment. Significant improvement was noted in VA for each group during treatment. VA increased by 0.39 logMAR units in group 1 (P = 0.00) and 0.35 logMAR units in group 2 (P = 0.00). There was no statistically significant difference between the 2 groups concerning visual improvement (P = 0.33) and reduction in retinal lesion size and activity. There were totally 22 cases who experienced recurrences during the follow up period (4 [11.1%] patients of control group and 18 [50%] of intervention group [P = 0.00]), indicating significant lower recurrence in control group. Treatment tolerance was significantly better for the azithromycin group due to lower adverse drug reactions (P = 0.00).

Conclusion: Azithromycin at a dose of 250 mg/d was shown to be effective for the treatment of active, non-vision threatening toxoplasmic retinochoroiditis similar to classic treatment with Pyrimethamine/Sulfadiazine regimen. However, recurrences and adverse drug reactions seem to differ significantly which notes the need for further studies and also vigilant selection of treatment protocols.

 

Cite By, Google Scholar

Google Scholar

Articles by Eftekhari Milani A
Articles by Bagheri M

PubMed

Articles by Masood Bagheri

Submit Paper
Online Submission System
CJMB ENDNOTE ® Style Tutorials Women's Reproductive Health Research Center
Publication Information
Publisher
Aras Part Medical International Press Editors in Chief
Arash Khaki
Editor
Zafer Akan Deputy Editor
Javadi, Leila
Published Article Statistics